Going Beyond MMR to the Analysis of Deep Molecular Response

Conference: AMP 2017

View PDF

Liquid Biopsy Analysis of NSCLC Patient Plasma Using ddPCR and NGS

Conference: AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics 2017

View PDF

Immunotherapy biomarker assessment in FFPE samples from solid tumors using IHC, gene expression profiling and mutation burden assessment

Conference: AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics 2017

View PDF

Gene and Protein Expression Of MAGE, PD‑L1 and Associated Immune Landscape Elements in Non‑small Cell Lung Carcinoma, Urothelial Carcinoma, Squamous Cell Cancer Of The Head And Neck, and Cervical Carcinoma

Conference: AACR-NCI-EORTC Moelcular Targets and Cancer Therapeutics 2017

View PDF

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

Source: N Engl J Med 2010; 362:2251-2259

Visit Link

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Source: N Engl J Med 2010; 362:2260-2270

Visit Link

Continued Superiority of Nilotinib vs Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd Beyond 1 Year

Source: Haematologica 2010; 95[suppl.2]:459, abs. 1113

Visit Link

A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial

Source: Blood (ASH Annual Meeting Abstracts) 2010 116: Abstract 6

Visit Link

A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings

Source: Blood (ASH Annual Meeting Abstracts) 2010 116: Abstract 210

Visit Link

Subset Analysis of Response to Treatment of Chronic Phase CML in a Phase 1 Study of Ponatinib in Refractory Hematologic Malignancies

Source: ASH Annual Meeting 2011; Presentation #602

Visit Link

Updated Phase 1 Data on Ponatinib, a Pan-BCR-ABL Inhibitor, in CML and Other Hematologic Malignancies

Source: ESH-iCMLf 13th International Conference, September 2011

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

Source: The Lancet Oncology; Volume 12, Issue 9, September 2011, Pages 841–851

Visit Link

ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Source: ASH Annual Meeting 2011; Presentation #207

Visit Link

Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up

Source: ASH Annual Meeting 2011; Presentation #206

Visit Link

Dasatinib and Imatinib-Induced Reductions in BCR-ABL Transcript Levels Below 10% At 3 Months Are Associated with Improved Responses in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Analysis of Molecular Response Kinetics in the DASISION Trial

Source: ASH Annual Meeting 2011; Presentation #2767

Visit Link

A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings

Source: ASH Annual Meeting 2011; Presentation #210

Visit Link

PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.

Source: J Clin Oncol 30, 2012 (suppl; abstr 6503)

Visit Link

Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up.

Source: J Clin Oncol 30, 2012 (suppl; abstr 6504)

Visit Link

Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up.

Source: J Clin Oncol 30, 2012 (suppl; abstr 6505^)

Visit Link

Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u).

Source: J Clin Oncol 30, 2012 (suppl; abstr 6509^)

Visit Link

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

Source: Leukemia doi:10.1038/leu.2012.134

Visit Link

RNA Quantitation Platform Comparison: nCounter, RT-qPCR, ddPCR

Conference: Next Generation Dx Summit 2016

View PDF

Oncomine Focus Assay: simultaneous detection of clinically relevant hotspot mutations, CNVs and gene fusions in 52

Conference: AACR Annual Meeting 2016
Abstract: 1397

View PDF

Detection of a Novel RET Gene Fusion in a Non-Small Cell Lung Cancer Patient Using AMP Chemistry

Conference: Fourth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic 2016
Abstract: A16

View PDF

Mutation Profiling of Colorectal Cancer ctDNA Using Ampliseq CHP2 Cancer Panel

Conference: AACR-NCI- EORTC International Meeting 2015
Abstract: A29

View PDF

Oncomine® Cancer Panel: simultaneous detection of clinically relevant hotspot mutations, CNVs and gene fusions in solid tumors

Conference: AACR 2015

View PDF

Liquid Biopsy using the Ion AmpliSeq v2 Cancer Panel

Conference: AACR 2015

View PDF

Development and Validation of a NOTCH Custom NGS Assay for Identifying NOTCH1 Mutations in Chronic Lymphocytic Leukemia and Other Lymphoid Malignancies

Conference: EHA 2014
Abstract: P861

View PDF

Droplet digital PCR A1:C31 of BRAF and NRAS plasma DNA as biomarkers of treatment response in stage IV melanoma

Conference: ASCO 2014

View PDF

Quantitative Assessment of circulating BRAF DNA on stage IV melanoma patients undergoing BRAF inhibitor treatment

Conference: AACR 2014

View PDF

Phasing Analysis of TKI Resistance Mutations in the BCR-ABL1 Kinase Domain and Neighboring Domains Using Next-Generation Sequencing

Conference: ASH 2013
Abstract: 3817

View PDF

Development and Validation of Highly Sensitive MRDx BCR-ABL Test for Monitoring Deep Molecular Response in Patients with Chronic Myeloid Leukemia

Conference: ASH 2013
Abstract: 2617

View PDF

Liquid Biopsy: Analytical Validation of a Plasma-Based BRAF V600 AS-PCR Assay

Conference: SMR 2013

View PDF

FFPE DNA Quality: Impact on Downstream Performance in Molecular Diagnostic Assays

Conference: AMP 2013
Abstract: ID102

View PDF

Obtaining Maximal Information from Limited FFPE Tissue Specimens: Development and Validation of a 4-Gene Custom NGS Panel for a GIST Clinical Trial

Conference: MC13-0069 Markers in Cancer
Abstract: MC13-6009

View PDF

Mutation detection in FFPE and plasma circulating DNA with a focused ALK-EGFR-KRAS Next-Generation Sequencing panel

Conference: AACR-EORTC 2013
Abstract: A208

View PDF

Evaluation of HGF and MET protein expression in NSCLC tumor specimens from patients previously treated with target or chermotherapies

Conference: AACR-EORTC 2013
Abstract: A42

View PDF

Clinical assessment of MUC1 protein expression in FFPE tissue: Development and validation of an immunohistochemistry assay as a predictive assay for response to MUC1 vaccines

Conference: AACR_EORTC 2013
Abstract: B297

View PDF

Analysis of plasma-based BRAF and NRAS mutation detection in patients with stage III and IV melanoma

Conference: ASCO 2013

View PDF

Validation of Illumina TruSeq Amplicon Cancer Panel with Concordance Testing Using Ion AmpliSeq Cancer Panel and Other Methods

Conference: AACR 2013
Abstract: 3229

View PDF

Complementary Analysis of LKB1/STK11 Mutation and Protein Expression Status using Next-Generation Sequencing, Sanger Sequencing and Immunohistochemistry

Conference: AACR 2013
Abstract: 3509

View PDF

Highly Sensitive Detection of EGFR T790M on Ion Torrent PGM

Conference: AACR 2013
Abstract: 3490

View PDF

Absolute Quantification of EGFR Activation and Resistance Mutations by Droplet Digital PCR in Circulating Nucleic Acids

Conference: AACR 2013
Abstract: 3491

View PDF

Clinical Assessment of PTEN mutation in FFPE Tissue: Comparison of Sanger Sequencing, Immunohistochemistry and Chomogenic In Situ Hybridization Methods

Conference: AACR 2013
Abstract: 39

View PDF

Non-Invasive Absolute Quantification of EGFR Activating Mutation L858R and Gatekeeper Mutation T790M in NSCLC Plasma Samples Using Droplet Digital PCR

Conference: EORTC 2012
Abstract: 450

View PDF

QX100 ddPCR Assay Development and Optimization for EGFR T790M Mutation: Identification in CNAs

Conference: Biorad 2012

View PDF

Next-Generation Sequencing of the BCR-ABL1 Kinase Domain and Neighboring Domains Associated with Therapy Resistance

Conference: ASH 2012
Abstract: 2549

View PDF

Analytical Validation of Ion AmpliSeq Cancer Panel 2.0

Conference: AMP 2012

View PDF

Liquid Biopsy: the Application of Allele-Specific PCR (AS-PCR) and Mutation-Directed SNaPshot Assay to Detect BRAF and NRAS Mutant DNA in Peripheral Blood from Metastatic Melanoma Patients

Conference: AMP 2012
Abstract: ST57

View PDF

Beyond V600E: Comprehensive genotyping of BRAF codon 600

Conference: AMP 2011

View PDF

Sensitivity of plasma BRAFmutant and NRASmutantcell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression

Publication: Molecular Oncology 10 (2016) 157-165

View PDF

Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Conference: ASH Annual Meeting 2013
Abstract: 652

Visit Link

Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells

Publication: Molecular Cancer Therapeutics, May 2013, Volume 12 Issue 5

Visit Link

Multivariate analyses of the clinical and molecular parameters associated with efficacy and safety in patients with CML and Ph+ ALL treated with ponatinib in the PACE trial

Conference: ASH Annual Meeting 2012
Abstract: 3747

Visit Link

A pivotal phase 2 trial of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 12 month follow-up of the PACE trial

Conference: ASH Annual Meeting 2012
Abstract: 163

Visit Link

Efficacy and safety of ponatinib according to prior approved tyrosine kinase inhibitor (TKI) therapy in patients with CML in chronic phase: results from the PACE trial

Conference: ASH Annual Meeting 2012
Abstract: 3749

Visit Link

Efficacy and safety of ponatinib in patients with accelerated phase or blast phase CML or Ph+ ALL: 12-month follow-up of the PACE trial

Conference: ASH Annual Meeting 2012
Abstract: 915

Visit Link

Molecular responses with ponatinib in patients with Philadelphia chromosome positive (Ph+) leukemia: results from the PACE trial

Conference: ASH Annual Meeting 2012
Abstract: 3763

Visit Link

The BCR-ABL315INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Abstract: 5250

Visit Link

Initial findings from the PACE trial: a pivotal phase 2 study of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation

Conference: ASH Annual Meeting 2011
Abstract: 109

Visit Link

Validation of Paxgene tubes for BCR-ABL quantitation at MMR value using 105 paired samples

Abstract: H23
Publication: Journal of Molecular Diagnostics 2007, Vol 9, No. 5

Visit Link

An MMR control RNA for reliable monitoring of BCR-ABL transcripts in treated CML patients

Conference: ASH Annual Meeting 2007
Abstract: 2939

Visit Link

A novel, high-throughput assay for detection of ABL T315I mutations

Conference: First AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, Sep 12-15, 2006
Abstract: B68

Visit Link